MARKET

XFOR

XFOR

X4 Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.62
+0.08
+0.94%
Closed 16:41 06/01 EDT
OPEN
8.68
PREV CLOSE
8.54
HIGH
8.85
LOW
8.50
VOLUME
93.43K
TURNOVER
--
52 WEEK HIGH
17.38
52 WEEK LOW
5.84
MARKET CAP
139.15M
P/E (TTM)
-2.5025
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average XFOR stock price target is 20.00 with a high estimate of 25.00 and a low estimate of 14.00.

EPS

XFOR News

More
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 14h ago
X4 Pharmaceuticals to Present at Two June Virtual Investor Conferences
GlobeNewswire · 4d ago
X4 Pharmaceuticals Announces Data from Phase 2 Open-Label Extension Trial of Mavorixafor in WHIM Syndrome as Published in EHA Abstract
Business Wire · 05/14 14:05
X4 Pharma To Present Data From Phase 2 Open-Label Extension Trial Of Mavorixafor In WHIM Syndrome At European Hematology Association Congres
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, disclosed efficacy and safety data from the Phase 2
Benzinga · 05/14 13:23
Arsanis Inc (XFOR) Moves to Buy: Rationale Behind the Upgrade
Zacks · 05/13 17:00
X4 Pharmaceuticals Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
Business Wire · 05/12 21:16
X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/09 21:23
B. Riley FBR Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $15
B. Riley FBR maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers the price target from $19 to $15.
Benzinga · 05/08 14:12

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About XFOR

X4 Pharmaceuticals, Inc., formerly Arsanis, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases including primary immunodeficiencies and cancer. The Company’s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. Its product candidates include X4P-001, X4P-002 and X4P-003.
More

Webull offers kinds of X4 Pharmaceuticals Inc stock information, including NASDAQ:XFOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XFOR stock news, and many more online research tools to help you make informed decisions.